ResearchSNDX

SNDX: FY25 Deep Dive

Ddrillr ResearchOriginal research

Published Sep 3, 20261 min read

Syndax Pharmaceuticals FY25 at $172M. NI $-285M; EPS $-3.30.

FY25 revenue $172M; OI $-273M; NI $-285M; EPS $-3.30.

Syndax Pharmaceuticals FY25 (Dec 31, 2025) at $172M revenue. OpInc $-273M; NI $-285M; EPS $-3.30. Biotech — Oncology.

Companies in this article